Aptevo Therapeutics Inc.
| NASDAQ: APVO |
| Healthcare / Biotechnology / USA |
| 3.88 | -0.1300 | -3.24% | Vol 50.75K | 1Y Perf -83.69% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 3.75 | ASK | 3.95 | ||
| Open | 4.02 | Previous Close | 4.01 | ||
| Pre-Market | - | After-Market | 3.80 | ||
| - - | -0.08 -2.06% |
| Target Price | 28.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 621.65 | Finscreener Ranking | + 37.81 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ☆ 30.48 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ☆ 26.61 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 3.85 | Earnings Rating | Sell | |
| Market Cap | 19.43M | Earnings Date | 11th Aug 2022 | |
| Alpha | -0.00 | Standard Deviation | 0.78 | |
| Beta | 6.33 |
Today's Price Range 3.824.10 | 52W Range 3.0325.13 | 5 Year PE Ratio Range -1.2022.70 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 11.49% | ||
| 1 Month | -19.83% | ||
| 3 Months | -36.08% | ||
| 6 Months | -50.70% | ||
| 1 Year | -83.69% | ||
| 3 Years | 340.91% | ||
| 5 Years | 69.43% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -52.69 | |||
ROE last 12 Months | -1 432.45 | |||
ROA (5Y Avg) | -30.41 | |||
ROA last 12 Months | -52.49 | |||
ROC (5Y Avg) | -43.38 | |||
ROC last 12 Months | -211.02 | |||
Return on invested Capital Q | -29.86 | |||
Return on invested Capital Y | -29.86 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 4.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.60 | ||||
| 19.27 | ||||
| 1.34 | ||||
| - | ||||
| -0.90 | ||||
| -4.00 | ||||
| -2.96 | ||||
| -1.18 | ||||
| -11 696 800.00 | ||||
| Forward PE | -0.59 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.60 | ||||
| 1.70 | ||||
| 0.81 | ||||
| 13.75 | ||||
| - | ||||
| Leverage Ratio | 15.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 82.60 | ||||
| -155.00 | ||||
| -146.60 | ||||
| -329.90 | ||||
| -68.62 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.99M | ||||
| 2.59 | ||||
| -28.67 | ||||
| -23.90 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -1.15 | -1.59 | -38.26 |
| Q03 2021 | -1.48 | -1.45 | 2.03 |
| Q02 2021 | -1.95 | -1.78 | 8.72 |
| Q01 2021 | -1.62 | -1.74 | -7.41 |
| Q03 2020 | -2.05 | -2.15 | -4.88 |
| Q02 2020 | -2.27 | -2.10 | 7.49 |
| Q01 2020 | -2.55 | -2.42 | 5.10 |
| Q03 2019 | -3.36 | -3.22 | 4.17 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -1.33 | 0.00 | - |
| 9/2022 QR | -1.35 | 2.17 | Positive |
| 12/2022 FY | -6.24 | -15.56 | Negative |
| 12/2023 FY | -5.47 | -16.14 | Negative |
| Next Report Date | 11th Aug 2022 |
| Estimated EPS Next Report | -1.33 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 50.75K |
| Shares Outstanding | 5.01K |
| Shares Float | 4.96M |
| Trades Count | 301 |
| Dollar Volume | 199.80K |
| Avg. Volume | 138.09K |
| Avg. Weekly Volume | 70.77K |
| Avg. Monthly Volume | 126.88K |
| Avg. Quarterly Volume | 216.63K |
Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 3.88 per share at the end of the most recent trading day (a -3.24% change compared to the prior day closing price) with a volume of 50.75K shares and market capitalization of 19.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.
The one-year performance of Aptevo Therapeutics Inc. stock is -83.69%, while year-to-date (YTD) performance is -50.7%. APVO stock has a five-year performance of 69.43%. Its 52-week range is between 3.03 and 25.1326, which gives APVO stock a 52-week price range ratio of 3.85%
Aptevo Therapeutics Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 19.27, a price-to-sale (PS) ratio of 1.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.49%, a ROC of -211.02% and a ROE of -1 432.45%. The company’s profit margin is -68.62%, its EBITDA margin is -146.60%, and its revenue ttm is $12.99 Million , which makes it $2.59 revenue per share.
Of the last four earnings reports from Aptevo Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.33 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $28, which is +621.65% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.39, ATR14 : 0.47, CCI20 : -38.34, Chaikin Money Flow : -0.48, MACD : -0.26, Money Flow Index : 15.69, ROC : -29.71, RSI : 44.41, STOCH (14,3) : 24.36, STOCH RSI : 0.86, UO : 51.92, Williams %R : -75.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were: Barbara Lopez Kunz (Option Excercise at a value of $0), Daniel J. Abdun-Nabi (Option Excercise at a value of $0), Grady Grant (Option Excercise at a value of $0), Jeffrey G. Lamothe (Option Excercise at a value of $0), Marvin L. White (Option Excercise at a value of $0), So Young Kwon (Option Excercise at a value of $0), Zsolt Harsanyi (Option Excercise at a value of $0)
Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.
CEO: Marvin L. White
Telephone: +1 206 838-0500
Address: 2401 4th Avenue, Seattle 98121, WA, US
Number of employees: 80
